tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Pharvaris price target raised to $41 from $37 at Morgan Stanley
PremiumThe FlyPharvaris price target raised to $41 from $37 at Morgan Stanley
23d ago
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
Premium
Ratings
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
23d ago
Pharvaris price target raised to $38 from $28 at Leerink
Premium
The Fly
Pharvaris price target raised to $38 from $28 at Leerink
23d ago
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
PremiumCompany AnnouncementsPharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
23d ago
Pharvaris’ deucrictibant meets primary endpoint in HAE attack trial
Premium
The Fly
Pharvaris’ deucrictibant meets primary endpoint in HAE attack trial
23d ago
Pharvaris Reports Q3 2025 Financial Results and Updates
Premium
Company Announcements
Pharvaris Reports Q3 2025 Financial Results and Updates
29d ago
Six new option listings on October 24th
PremiumThe FlySix new option listings on October 24th
2M ago
3 Best Stocks to Buy Now, 10/23/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 10/23/2025, According to Top Analysts
2M ago
Pharvaris initiated with a Buy at H.C. Wainwright
Premium
The Fly
Pharvaris initiated with a Buy at H.C. Wainwright
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100